Formulation Through Manufacturing Under One Roof: One Emerging Biopharma’s Experience
Summary: Emerging biopharmas (EBPs) limited resources can result in a lack of direct access to manufacturing, knowledge about product formulation and presentation, or understanding of the regulatory requirements of drug development. In this case study, learn how Catalent’s formulation development and integrated manufacturing services can help EBPs through the complexities of the drug development process.